Exelixis | Себестоимость



Cost Of Sales Изменить Дата
Acadia Pharmaceuticals USD 21.8M 2.95M 2024-12
Agios Pharmaceuticals USD 1.26M 477K 2024-12
Amgen USD 3.11B 198M 2024-12
AstraZeneca USD 2.72B 263M 2024-12
Bayer EUR 5.72B 633M 2024-12
BioMarin Pharmaceutical USD 136.14M 52.32M 2024-12
Bristol-Myers Squibb USD 3.21B 356M 2024-12
Cytokinetics 463K 79.14M 2024-09
Eisai JPY 45.94B 3.42B 2024-12
Eli Lilly USD 2.4B 233M 2024-12
Exelixis USD 19.96M 2.64M 2025-01
Genmab DKK 337M 64M 2024-12
Glaxosmithkline GBP 2.52B 199M 2024-12
Incyte USD 82.38M 2.49M 2024-12
Ionis Pharmaceuticals USD 3.83M 2.76M 2024-12
MacroGenics USD 5.49M 3.62M 2024-12
Merck USD 3.71B 181M 2024-12
Moderna USD 546M 246M 2024-12
Neurocrine Biosciences USD 9.3M 1.3M 2024-12
Novartis USD 3.32B 90M 2024-12
Pfizer USD 5.65B 781M 2024-12
Sanofi EUR 2.27B 1.81B 2024-12
Takeda JPY 416.87B 22.56B 2024-12
Ultragenyx Pharmaceutical USD 16.89M 4.13M 2024-12
Xencor 10.71M 4.56M 2024-09



Exelixis Себестоимость - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - Apr 2025.